QM · rank #16 · 2026-10-22
ETON
NASDAQ · $1.43B (USD)
The exact numbers the algorithm saw.
| Momentum 12-1 Return from 12 months ago to 1 month ago. | +210.78% |
|---|---|
| ROE TTM Return on equity, trailing 12 months. | +36.0% |
| Profit margin Net profit margin, trailing 12 months. | +12.0% |
| Market cap (USD) Size filter: > $500M required. | $1.43B |
| Anchor (recent) Close on 2026-09-22 | $57.09 |
| Anchor (far) Close on 2025-09-22 | $18.37 |
The AI research card
Independent qualitative review of each pick before the order is placed. On the rare day the research service is unavailable, the paper book trades on the quant ranking alone and no card appears here.
Summary
Eton Pharmaceuticals is a rare-disease commercialization platform with eleven commercial products, exclusive U.S. rights to IMPAVIDO and LIBERVANT, and a pipeline anchored by licensed and acquired specialty assets.
Rationale
The momentum_12_1 of 2.11 and ROE of 36% are directly supported by a real fundamental catalyst — Q2 revenue nearly doubling YoY to $37.6M, raised 2026 guidance to $145M+, and IMPAVIDO's commercial launch — making the quality-momentum signal structurally grounded rather than sentiment-only.
Material risks
- 1LIBERVANT's revenue contribution is contingent on final FDA approval targeted April 2027; a rejection or delay removes a key pillar of the $145M guidance and would directly disconfirm the forward earnings quality thesis.
- 2Eton's model depends on licensed/acquired products with no broad patent moat — loss or renegotiation of exclusive commercialization rights for IMPAVIDO or LIBERVANT would materially impair the platform's revenue visibility and ROE sustainability.
AI verdict council
Each pick is reviewed independently by 3 models before any order. 3 of 3 voted to proceed.